CYP17 promotor polymorphism and ovarian cancer risk.
Spurdle AB, Chen X, Abbazadegan M, Martin N, Khoo SK, Hurst T, Ward B, Webb PM, Chenevix-Trench G.
Spurdle AB, et al.
Int J Cancer. 2000 May 1;86(3):436-9. doi: 10.1002/(sici)1097-0215(20000501)86:3<436::aid-ijc21>3.0.co;2-a.
Int J Cancer. 2000.
PMID: 10760835